Background/Aim: Liver resection and liver transplantation offer the best chance of survival in hepatocellular carcinoma (HCC), but tumor recurrence still occurs frequently, warranting patient stratification according to the risk of recurrence. Enrichment in stem cell markers is currently a possible risk stratifying strategy. The prognostic significance for HCC recurrence of CD44, a well-established stem cell marker, is still controversial. The aim of our study was to investigate the prognostic significance of CD44 expression in hepatocellular carcinoma following a potentially curative treatment. Methods: CD44 expression was investigated by qRT-PCR and immunohistochemistry in 31 patients who underwent a potentially curative treatment for HCC. Multivariate survival analysis was conducted using Cox proportional hazards model. Patient HCC related death according to CD44 expression was investigated by Kaplan Meier method. Results: mRNA quantification has indicated a significant down regulation of CD44 in tumoral vs nontumoral tissue in 35.7% of cases and a significant up-regulation of gene expression in 9.5% of cases. Immunohistochemistry has indicated positive CD44 staining in both tumoral and non-tumoral tissue, mainly in non-parenchymal cells and also in a subset of tumoral hepatocytes. CD44 relative gene expression was the only independent predictor of early tumor recurrence, independent of clinical variables as well as for one-year tumor related death. In conclusion our study brings new evidence for the negative prognostic significance of CD44 expression in hepatocellular carcinoma, indicating a subgroup of patients that need aggressive follow-up after a potentially curative treatment, independent to the kind of surgical treatment performed (liver transplantation or liver resection).
INTRODUCTION INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth most common neoplasm in the world and the third cause of cancer related death. Each year there are 792,000 new cases and 818,000 liver cancer related deaths (1) .
Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, Bucharest, Romania HCC represents more than 90% of liver cancers and develops in 80% of cases in patients with cirrhotic livers (2) . Despite advances in prevention techniques, screening, and new technologies in diagnosis and treatment, incidence and mortality continue to rise. Hepatitis B virus and hepatitis C virus leading to cirrhosis remain the most powerful risk factors for HCC, conferring an annual risk of developing HCC of approximately 5%.
Selection of a treatment modality is based on tumor size, location, extrahepatic spread, underlying liver function and usually requires a multidisciplinary approach (3) . Liver resection and liver transplantation are the main therapeutic curative options in the case of HCC with or without associated liver cirrhosis.
However, the 1-, 3-, and 5-year survival have been reported to be 85%, 62%, and 51% for resection and 84%, 69%, and 69% for transplantation for patients with early HCC (4) .
Consequently to the poor prognosis of this cancer, a translational approach is required to personalized clinical decision making, to improve survival of HCC patients. Molecular signatures derived from tumor and non-tumor samples are associated with early tumor recurrence due to metastasis and late tumor recurrence due to de novo carcinogenesis after curative treatment, respectively. Identification of patients with a high risk of relapse will guide adjuvant therapy randomized clinical trials and also select patients that require aggressive follow-up for detection of an early tumor recurrence (5).
There have been described cells within the HCC cellular population that express stem/progenitor cells specific markers, designating tumor stem cells. Several cell surface markers have been proposed for identification of HCC stem cells both in vivo and in vitro (6): CD13, CD133, CD24, CD44, CD90, DLK1, EPCAM, OV6 (7) (8) (9) CD44 has been reported to have multiple functions related to migration, adhesion and invasion and prognostic significance has been investigated in many cancers: liver, kidney, thyroid gland, colorectal (10) .
In the liver, CD44 is a major receptor for hyaluronic acid and osteopontin, critical mediators of fibrogenesis in cirrhosis and has been investigated by multiple studies in relationship with clinicopathological features of HCC or as a prognostic factor, so far with conflicting results (11) (12) (13) .
The aim of our study was to investigate CD44 expression pattern in HCC and its prognostic significance following a potentially curative treatment (liver resection or liver transplantation).
MATERIALS AND METHODS MATERIALS AND METHODS
Thirty one patients following a potentially curative treatment for HCC in a Tertiary Digestive Diseases Centre have been consecutively included in our study. Tissue specimens have been harvested at the time of surgery by the pathologist and preserved in our Hospital Tissue Bank. Liver transplantation policy in our Center has been previously described (14) . All patients provided informed consent for tissue prelevation and tissue banking for participation in the study.
Patients follow-up
The following clinical variables were recorded preoperatively and after the histopathological analysis of the surgical specimen: age, sex, liver disease etiology, Child-Pugh classification of underlying liver disease, number of tumors, maximal tumor diameter, preoperative AFP levels, Edmondson-Steiner grading. Only patients with a histologically proven HCC were included in the study. After treatment, patients were followed-up by abdominal ultrasound every three months, abdomen and chest CT scans and AFP level every 6 months during the first two years and yearly thereafter. Tumor recurrence and patient death were recorded for survival analysis.
Liver tissue samples
Tumoral (T) and paired non -tumoral cirrhotic tissue samples (C) were collected by a trained pathologist from surgical specimens immediately after procedure (liver resection or liver transplantation), stored in RNALater (Sigma, St. Louis, MO) and deep-frozen in liquid nitrogen subsequently. For transcriptomic analysis total RNA was isolated from frozen tumoral and non-tumoral tissue samples using TRI Reagent ® (Sigma, St. Louis, MO) according to recommended protocol.
RNA extraction and quantitative gene expression analysis
Total RNA was purified from tissue samples using RNEasy Mini kit (Qiagen) according to manufacturer's instructions. The quantity and quality of the total RNA were assessed by spectrophotometry with Nano Drop 1000 (Thermo Scientific, Arlington, TX) and by using lab-on-a-chip Agilent 2100 technology (Agilent Technology, Santa Clara, CA). Only samples with RNA Integrity Number higher that 8.0 were used for further analysis. 1 ug RNA/sample was subjected to reverse transcription using RT2 First Strand Kit (Qiagen). Gene expression quantification has been performed in duplicate using a Custom RT2 Profiler PCR Array (Qiagen).
Beta-actin was used as internal control gene.
The custom made array uses validated primer pairs and has multiple qPCR quality controls: genomic DNA contamination control, reverse transcription control, positive qPCR control. Fold changes in gene expression were calculated in comparison T vs C tissue samples, using comparative Ct method [2^(-delta delta Ct)]. Significant down regulation was considered for < 0.5 fold change in relative gene expression, significant upregulation for >2 fold change.
Immunohistochemistry
Immunohistochemistry was conducted on paraffin embedded tissue samples using CD44 Monoclonal Antibody (156-3C11) (Thermo Fisher Scientific) and UltraVision Quanto Detection System HRP DAB (Thermo Fisher Scientific) according to manufacturer's instructions.
Statistical analysis
Quantitative data has been expressed as mean ± standard deviation. Categorical data has been expressed as percentage of patients in a specific category. Multivariate survival analysis has been conducted by Cox proportional hazards model, having early tumor recurrence (within 24 months) as an outcome. CD44 relative gene expression was included as a covariate in the multivariate analysis, together with clinical variables. Survival curves have been depicted as Kaplan Meier plots and compared using log-rank test. A p-value <0.05 has been used for statistical significance.
RESULTS RESULTS
In our cohort, tumor recurrence was diagnosed in 51.6% of patients following a potentially curative treatment with highest rate in patients following livingrelated liver transplantation. Patient's tumor relateddeath during follow-up occurred in 25.8% of cases. Patient's characteristics are depicted in table 1. mRNA quantification has indicated a significant down regulation of CD44 in tumoral vs non-tumoral tissue in 35.7% of cases and a significant up-regulation of gene expression in 9.5% of cases.
Immunohistochemical staining of tumoral and nontumoral adjacent tissue has indicated positive CD44 expression in non-parenchymal cells in both tumor and adjacent cirrhotic tissue, in all the studied cases.
The number of positive non-parenchymal cells, however, was lower in a subset of tumoral nodules as compared to non-tumoral tissue, in concordance with the mRNA gene expression ( fig. 1) . The cells marking the border between tumor and cirrhotic adjacent tissue were also CD44 positive ( fig. 2) .
CD44 positive clustered tumoral hepatocytes were identified in a subset of tumors ( fig. 3) .
There was no statistically significant correlation between CD44 mRNA expression levels and clinical variables: age, sex, disease etiology, AFP level, Edmondson-Steiner grading, Child-Pugh class, number of tumors, the diameter of the largest tumor or the distribution of patients according to Milan criteria (table 2) .
The predictive value of CD44 relative gene quantification for early tumor recurrence (in the first 24 months following the therapeutic procedure) was investigated by Cox proportional hazards regression. The following variables have been included as covariates in the multivariate survival analysis: CD44 relative gene expression, AFP > 300 ng/ml, EdmondsonSteiner grading -Well -differentiated, Milan criteria, type of surgical procedure. CD44 relative gene expression was the only independent predictor of early tumor recurrence (table 3) .
Significant tumoral up-regulation of CD44 (>2 fold change in relative gene expression) was also a predictor of early tumor related patient death following the therapeutic procedure, according to Kaplan Meier survival curves (p=0.03 -log rank test) ( fig. 4) .
DISCUSSION DISCUSSION
CD44 is an important adhesion molecule that mediates cellular-matrix interactions and also a documented mesenchymal stem cell marker involved in paracrine intercellular communication (15) . CD44 defines a family of class I transmembrane proteins produced by alternate splicing leading to variation in the extracellular membrane -proximal portion of the protein, encoded by variant exons v1-v10 (16) . It has been reported that spliced variant forms v6 and v7 of CD44 constitute binding sites for osteopontin (17) , a multifunctional protein with complex roles mediating inflammation, fibrogenesis, angiogenesis and carcinogenesis in multiple organs including the liver (18) . In the liver, CD44 is also a receptor for hyaluronic acid, an important mediator of liver fibrogenesis, being the main regulator for its metabolism (19) .
In the present study we have found supporting evidence for the prognostic significance of CD44 gene expression in hepatocellular carcinoma with regard to tumor recurrence after a potentially curative treatment, as well as for early patient death due to HCC recurrence. In our study CD44 was the only independent predictor of early tumor recurrence, stronger than classical clinical predictors, independent of the type of surgical procedure (liver resection or liver transplantation).
Although there are multiple studies investigating In the study conducted by Mima K et al, CD 44 expression was investigated in 5 HCC cell lines (PLC/PRF/5, HuH1, HLF, HLE and SK HEP-1), the authors concluding that CD44v6 expression is correlated with an invasive phenotype, but the result did not appear to be clinically significant. The study conducted by the same group in 150 HCC patients who underwent liver resection for HCC indicated only 30.7% positive for CD44v6 expression: 21.3% <25% positivity, 6% 25-50% positivity and 3.3% >50% positivity with no positive cell identified in adjacent liver tissue. There was a trend of association between a low CD44v6 expression and the vascular invasion in HCC patients and there was no significant association between high CD44v6 expression and disease-free survival, by Kaplan-Meier method (20) .
In contrast, Mathew et al have shown that high expression of CD44s (standard isoform of CD44) was associated with increased rate of vascular invasion (21) . In the study by Endo et al, CD44 protein expression correlated with reduced survival and was identified by multivariate survival analysis as the single independent prognostic factor (22) . In a study conducted on a cohort of 260 patients with HCC by tissue microarray analysis, CD44s protein expression correlated with histological grade (poorly differentiated according to Edmondson grading system) and was also identified by univariate and multivariate survival analysis as a negative prognostic factor (23). Expression of osteopontin and its main receptor CD44 was investigated at mRNA and protein level in tumor tissue and surrounding hepatic parenchyma, in 53 patients who underwent liver resection for HCC (24) . Expression of OPN and CD44s was significantly higher in HCC compared with adjacent non-tumor tissue both proteins being significantly overexpressed in HCC lesions with positive lymph nodes. However, there was no significant correlation between patient survival and OPN and CD44s expression (24) .
In our study, there was no significant difference in CD44 mRNA gene expression between tumor and nontumoral adjacent tissue in 54.8% of cases and overexpression of CD44 gene was identified in 9.5% of cases. There was strong expression of CD44 protein in cells located at the tumor margin, at the interface with the non-tumoral cirrhotic tissue, possibly marking the tumor invasion front. If these cells are positive CD44 hepatocyes or non-parenchymal cells is an important question to be answered by subsequent studies.
There is a clear difference between the expressions profiles of CD44 in human studies in comparison to studies conducted in animal models of liver injury. In a classical oval cells model, the rat model of liver injury induced by 2 acetylaminofluorene treatment followed by partial hepatectomy (2AAF-PH), Affymetrix analyses indicated high CD44 expression levels in the oval cells enriched fraction. Also hepatoblasts and FAO-1 hepatoma cells were positive for CD44. In normal rat liver, CD44 was positive in small bile ducts, co-localizing with CK19 and also in scattered blood-cells from the periportal region (also positive for CD45). In 2AAF/PH treated animals, CD44 was strongly positive in oval cells but not in endothelial cells, Kupfer cells or stellate cells (25) . According to our study, in liver cirrhosis mainly the non-parenchymal cells, probably liver endothelial cells or stellate cells, have a strong positive CD44 staining, supporting the idea that the oval cell theory is not applicable in the human setting of chronic liver disease. Due to ubiquitous expression of CD44 in both nontumoral and intra-tumoral nonparenchymal cells, our result also emphasise the important prognostic significance of the HCC environment in the cirrhotic context, more than the cancer stem cell theory. Although clusters of CD44 positive malignant hepatocytes could also be identified, the exact nature or origin of those cells is still elusive and should be investigated by subsequent co-localisation studies with other stem cell markers.
CONCLUSION CONCLUSION
In conclusion our study brings new evidence for the negative prognostic significance of CD44 expression in hepatocellular carcinoma indicating a subgroup of patients that need aggressive follow-up after a poten- tially curative treatment, irrespective of the type of treatment performed (liver transplantation or liver resection).
